Associated Papers
Diagnostic accuracy of next-generation sequencing (NGS) for identifying actionable mutations in advanced non-small cell lung cancer: Systematic Review and Meta-Analysis.
Téllez Castillo N et al.
Clinical & Translational Oncology : Official Publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico, 2026
A multiplex, prime editing framework for identifying drug resistance variants at scale.
Abadie FMC et al.
Cell Genomics, 2026
TP53 Functional-Domain-Specific Mutations Define Distinct Clinical Outcomes in EGFR-Mutant Non-Small Cell Lung Cancer Treated with EGFR Tyrosine Kinase Inhibitors.
Kobayashi K
Journal of Clinical Medicine, 2026
Genomic Profile of Non-Small Cell Lung Cancer in a Spanish Cohort: A 2-Year Descriptive Study Using Next-Generation Sequencing.
Carnero-Gregorio M et al.
Genes, 2026
ACSM5 c.1273 C> A Polymorphism Promotes Malignant Progression of Lung Adenocarcinoma in Xuanwei Region.
He C et al.
Applied Biochemistry and Biotechnology, 2026
Real-world clinical utility of comprehensive genomic profiling in advanced solid tumors.
Saito Y et al.
Nature Medicine, 2026
Individualized management strategies for advanced non-small cell lung cancer with EGFR exon 19 deletion and L861Q compound mutations based on circulating tumor DNA monitoring: A case report.
Zhu X et al.
Oncology Letters, 2026
Integrating evidence from protein domains to identify cancer driver mutations.
Ostroverkhova D et al.
Protein Science : a Publication of the Protein Society, 2026
First Line and Treatment Sequencing in EGFR-Mutated Metastatic NSCLC: What is Right for Which Patient?
Abdayem P et al.
Drugs, 2026
Integrative clinico-molecular analysis reveals actionable subtypes and biomarkers in lung adenocarcinoma.
Shang J et al.
Cell Discovery, 2026
An alternative EGFR activation by patient-derived R252C mutation promotes cancer progression.
Zhang Y et al.
Nature Communications, 2026
EGFR mutation spectrum and clinical correlations in Tunisian Non-Small cell lung cancer patients.
Abdelmaksoud-Dammak R et al.
Molecular Biology Reports, 2026
Targeting the Uncommon: A Case Report of Osimertinib Response in Advanced NSCLC Patient with Dual EGFR (E701fs and L702fs) Frameshift Deletions.
Wong AKQ et al.
Current Oncology (toronto, Ont.), 2026
Osimertinib with or without savolitinib as first-line treatment for MET-aberrant, EGFR-mutant NSCLC: randomized phase 2 trial (FLOWERS).
Li A et al.
Nature Communications, 2026
Application of pleural effusion cell blocks for immunohistochemistry and EGFR gene mutation testing for advanced lung cancer.
Zhao S et al.
Experimental and Therapeutic Medicine, 2026
Amivantamab Plus Lazertinib in Atypical EGFR-Mutated Advanced Non-Small Cell Lung Cancer: Results From CHRYSALIS-2.
Tomasini P et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology, 2026
Advances in the Basic Sciences in Thoracic Oncology in the Last 20 Years and Their Translational Impact.
Carbone M et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer, 2026
Case Report: A patient harboring rare EGFR S768I/V769L compound mutation benefited from afatinib and osimertinib.
Cui Q et al.
Frontiers in Pharmacology, 2026
Efficacy of TKIs in non-small cell lung cancer with atypical EGFR p.L747P and p.L747S mutations.
Hu Q et al.
Frontiers in Oncology, 2026
Common epidermal growth factor receptor mutations in north Indian patients with non-small cell lung carcinoma: evidence from real-time polymerase chain reaction.
Behera R et al.
Monaldi Archives for Chest Disease = Archivio Monaldi Per Le Malattie Del Torace, 2025
Establishment of a Flow Cytometry Protocol for Binarily Detecting Circulating Tumor Cells with EGFR Mutation.
Chang CY et al.
Diseases (basel, Switzerland), 2025
Germline EGFR T790M in Lung Cancer: Prevalence, Clinical Impact, and Implications for Hereditary Risk.
Melikova LA et al.
Cancer Prevention Research (philadelphia, Pa.), 2025
Coverage of actionable alterations in non-small cell lung cancer by hybrid capture-based FoundationOne®CDx compared with amplicon-based OncomineDX.
Chen KT et al.
The Oncologist, 2025
Germline EGFR T790M in Lung Cancer: Prevalence, Clinical Impact, and Implications for Hereditary Risk.
Melikova LA et al.
Cancer Prevention Research (philadelphia, Pa.), 2025
Analytical Validation of a Pan-Cancer Next-Generation Sequencing Assay for In-House Liquid Biopsy Testing: An International Multicenter Study.
Lescuyer G et al.
The Journal of Molecular Diagnostics : Jmd, 2025
Pattern of failure, impact of local therapy, and characteristics of long-term responders with advanced EGFR mutation positive non-small cell lung cancer treated with first-line osimertinib.
Chen ACC et al.
Lung Cancer (amsterdam, Netherlands), 2025
Two Cases of Epidermal Growth Factor Receptor L861R Mutation-Positive Lung Adenocarcinoma Treated With Osimertinib and Afatinib.
Kagawa K et al.
Cancer Reports (hoboken, N.j.), 2025
Somatic gene mutations and their association with treatment outcomes among Indo-Asian Lung Cancer patients.
Kulsum S et al.
Cancer Treatment and Research Communications, 2025
Immunotherapy in EGFR-mutant non-small cell lung cancer.
Wang L et al.
Clinical and Experimental Medicine, 2025
High clinical actionability of a pan-cancer tissue-based combined DNA and RNA next generation sequencing assay in a diverse Asian population.
Lee JY et al.
Npj Precision Oncology, 2025
Real-World Outcomes and Subsequent Treatment Patterns in Patients with Advanced Non-Small Cell Lung Cancer and Atypical EGFR Mutations Receiving First-Line Osimertinib Monotherapy.
Nieva JJ et al.
Oncology and Therapy, 2025
Case report: First report of metastatic esophageal squamous cell carcinoma with EGFR p.S768I mutation: remarkable response to third-generation EGFR-TKI.
Liu Y et al.
Npj Precision Oncology, 2025
Applying next-generation sequencing to predict short progression-free survival in patients with advanced EGFR -mutant lung adenocarcinoma receiving epidermal growth factor receptor tyrosine kinase inhibitors.
Lee PH et al.
Anti-cancer Drugs, 2025
Impact of Incidental Germline BRCA1/2 and PALB2 Alterations on EGFR Monotherapy Real-World Outcomes for Patients With Advanced Non-Small-Cell Lung Cancer.
Vakkalagadda CV et al.
Clinical Lung Cancer, 2025
Challenges associated with the treatment of E709K and L858R double mutation in lung adenocarcinoma: A case report and literature review.
Song J et al.
Oncology Letters, 2025
Safety and efficacy of YK-029A in previously treated EGFR T790M-Mutant NSCLC: A multi-center phase I trial.
Wu X et al.
Lung Cancer (amsterdam, Netherlands), 2025
Novel Resistance Mechanisms to Second-Generation EGFR Tyrosine Kinase Inhibitor Afatinib and Associations With Genomic Features in NSCLC.
Lin F et al.
Genes, Chromosomes & Cancer, 2025
Discriminating activating, deactivating and resistance variants in protein kinases.
Singh G et al.
Genome Medicine, 2025
Endotracheal and Endobronchial Metastases in Epidermal Growth Factor Receptor Exon 19 Deletion Lung Adenocarcinoma: A Case Successfully Managed with Bronchoscopic Therapy and Sequential Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors.
Fujiwara M et al.
Internal Medicine (tokyo, Japan), 2025
Genetic Alteration Profiling in North Macedonian Lung Cancer Patients.
Eftimov A et al.
Genes, 2025
Sensitive and Accurate Detection of Low-frequency Mutations via Pyrophosphorolysis-Activated Selective Amplification and MALDI-TOF-MS Single-Nucleotide Resolution Identification.
Liang S et al.
Journal of the American Chemical Society, 2025
A rare case of lung adenocarcinoma with uncommon epidermal growth factor receptor gene double mutations: S768I + G719X.
Mishra D et al.
Journal of Cancer Research and Therapeutics, 2025
Epidermal Growth Factor Receptor Aberrations Identified by Next-Generation Sequencing in Patients with Metastatic Cancers.
Shin M et al.
Cancer Research and Treatment, 2025
Discovery of Novel RASGRF2 Fusions as a Therapeutic Target in Lung Adenocarcinoma of Never or Light Smokers.
Terashima Y et al.
Cancer Science, 2025
Comprehensive Genomic Profiling in Advanced Non-Small Cell Lung Cancer: A Real-World Cohort Study in Finland.
Hormalainen K et al.
Cancer Medicine, 2025